Characterized to selectively mimic the phenotype associated with CDK12 loss of function using Recursion’s AI-powered maps of human biology.

Commit To Buy Recursion Pharmaceuticals At $7.50, Earn 32.7% Using Options May 31, 2024 — 11:39 am EDT Written by BNK Invest for BNK Invest -> ...

Recursion, a biotech company making new drugs using AI technology, just closed a $121 million Series C round with investors like the venture-capital firm Menlo Ventures.

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter ...

Most AI-driven biopharma companies parse available data to find drug molecules that target single proteins believed to underlie a disease. This yields a lot of leads, but few pan out. Recursion ...